Immunoprecise Antibodies Ltd Stock Toronto S.E.
Equities
TQY
CA87588T2020
Pharmaceuticals
Sales 2024 * | 24.59M 17.95M | Sales 2025 * | 29.82M 21.77M | Capitalization | 39.08M 28.53M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.76M | Net income 2025 * | -9M -6.57M | EV / Sales 2024 * | 1.59 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
-3.11
x | P/E ratio 2025 * |
-4.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
-1.62% | 90.85B | |
-1.05% | 39.02B | |
-11.20% | 33.46B | |
+62.29% | 26.38B | |
-20.75% | 14.51B | |
-6.35% | 13.22B | |
-11.42% | 11.65B | |
-47.67% | 10.57B | |
+7.12% | 9.23B |